
It caused a stir last week when Roche came out with harsh criticism of the conditions that international pharmaceutical companies operate under when conducting clinical research in Denmark.
A sudden and large rise in fees and different practices between regions and even between hospitals within the same region were among Roche's criticisms. The criticism was backed by several industry representatives, who believe that it is a threat to future research in Denmark.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app